Brief Hospitalization for Schizophrenia: Strategies to Improve Treatment Outcome
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
The goal of this research program is to implement a series of psychoeducational training classes designed to teach individuals with schizophrenia the importance of medication treatment, how to identify and manage medication side effects, and how to make appointments and emergency plans. The skills taught to the research subjects will lead to demonstrable increases (compared to the control group) in adherence to both the prescribed medication regimen and scheduled outpatient appointments and thereby cause a decrease (again compared to the control group) in rehospitalization rates and bed-days during subsequent twelve months following the intervention. A secondary objective of this work is that if the CREP program is successful and/or illness education is effective, the data will be able to disseminated throughout the VISN 22 via the recently awarded Mental Illness Research Education and Clinical Center (MIRECC) program.
Condition or disease
Behavioral: Community Re-Entry Program: What is Schizophrenia
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years to 65 Years (Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Age 18-65 years of age.
DSM IV diagnosis of schizophrenia or schizoaffective disorder.
Competent to give informed consent.
Previously participated in "Brief Hospitalization for Schizophrenia: Strategies to Improve Treatment Outcome" Principal Investigator. Donna Wirshing, M.D.
Physical or cognitive impairment of such severity as to adversely affect the validity of clinical ratings or impair capacity to give informed consent.
History of substantial substance dependence 6 months prior to the study.
Patients at high risk of suicide or other directed violence.